Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2011

01-12-2011 | Research Article

The expression of PEBP4 protein in lung squamous cell carcinoma

Authors: Gui-Ping Yu, Guo-Qiang Chen, Song Wu, Kai Shen, Yong Ji

Published in: Tumor Biology | Issue 6/2011

Login to get access

Abstract

The phosphatidylethanolamine-binding protein 4 (PEBP4) is a member of the PEBP family. It not only plays a role in the inhibition of the MAPK signaling pathway but also is involved in the inhibition of the JNK pathway that promotes the activation of AKT. Recent research has also shown that overexpression of PEBP4 was related to the development, invasion, and metastasis of a variety of tumors. This study aimed to investigate the correlation between PEBP4 protein expression in lung squamous cell carcinoma tissue and the clinical pathology of lung squamous cell carcinoma. Immunohistochemistry was used to detect PEBP4 expression in lung squamous cell carcinoma tissue and adjacent normal tissue from 61 patients. Western blotting was used to detect changes in the expression of PEBP4 protein between lung squamous cell carcinoma tissue and adjacent normal tissues. The correlation of PEBP4 expression and the occurrence, development, and clinical pathology of lung squamous cell carcinoma was analyzed. Of 61 patients, four patients were PEBP4 negative (−; 6.6%) and 57 patients were positive (+ to +++; 93.4%). Of those positive for PEBP4 expression, 7 patients were weakly positive (+; 11.5%), 21 patients were positive (++; 34.4%), and 29 patients were strongly positive (+++; 47.5%). PEBP4 protein was more highly expressed in lung squamous cell carcinoma tissue than in the adjacent normal lung tissue (p < 0.05). In PEBP4-positive patients, PEBP4 protein expression was significantly greater in those with lymph node metastases than in those without (p < 0.05). PEBP4 expression was significantly lower in patients at early (I and II) stages than in patients at advanced (III and IV) stages (p < 0.05). In less differentiated lung squamous cell carcinomas, PEBP4 protein expression was greater (p < 0.05); however, this was unrelated to the gender, age, or tumor size of the patient (p > 0.05). PEBP4 protein overexpression was associated with the occurrence, invasion, and metastasis of lung squamous cell carcinoma.
Literature
1.
Garcia R, Grindlay J, Rath O, et al. Regulation of human myoblast differentiation by PEBP4. EMBO Rep. 2009;10:278–84.PubMedCrossRef
2.
Amaya I, Ratcliffe OJ, Bradley DJ. Expression of CENTRORADIALIS (CEN) and CEN-like genes in tobacco reveals a conserved mechanism controlling phase change in diverse species. Plant Cell. 1999;11:1405–18.PubMedCrossRef
3.
Erttmann KD, Gallin MY. Onchocerca volvulus: identification of cDNAs encoding a putative phosphatidyl-ethanolamine-binding protein and a putative partially processed mRNA precursor. Gene. 1996;174:203–7.PubMedCrossRef
4.
Wilson R, Ainscough R, Anderson K, et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature. 1994;368:32–8.PubMedCrossRef
5.
Kikuchi R, Kawahigashi H, Ando T, et al. Molecular and functional characterization of PEBP genes in barley reveal the diversification of their roles in flowering. Plant Physiol. 2009;149:1341–53.PubMedCrossRef
6.
Odabaei G, Chatterjee D, Jazirehi AR, et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169–200.PubMedCrossRef
7.
Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173–7.PubMedCrossRef
8.
Corbit KC, Trakul N, Eves EM, et al. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003;278:13061–8.PubMedCrossRef
9.
Shemon AN, Heil GL, Granovsky AE, et al. Characterization of the Raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands. PLoS One. 2010;5:e10479.PubMedCrossRef
10.
Al-Mulla F, Bitar MS, Al-Maghrebi M, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Res. 2011;71:1334–43.PubMedCrossRef
11.
Zaravinos A, Chatziioannou M, Lambrou GI, et al. Implication of RAF and RKIP genes in urinary bladder cancer. Pathol Oncol Res. 2011;17:181–90.PubMedCrossRef
12.
Wang X, Li N, Liu B, et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem. 2004;279:45855–64.PubMedCrossRef
13.
Qiu J, Xiao J, Han C, et al. Potentiation of tumor necrosis factor-alpha-induced tumor cell apoptosis by a small molecule inhibitor for anti-apoptotic protein hPEBP4. J Biol Chem. 2010;285:12241–7.PubMedCrossRef
14.
Liu H, Qiu J, Li N, et al. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src. J Biol Chem. 2010;285:21934–42.PubMedCrossRef
15.
Zhu XL, Liang L, Ding YQ. Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis. 2008;23:1041–7.PubMedCrossRef
16.
Vora HH, Patel NA, Rajvik KN, et al. Cytokeratin and vimentin expression in breast cancer. Int J Biol Markers. 2009;24:38–46.PubMed
17.
Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: are we making progress? J Thorac Dis. 2011;3:19–29.
18.
Shao WL, Wang DY, He JX. The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis. 2010;2:89–99.
19.
Wang X, Li N, Li H, et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005;11:7545–53.PubMedCrossRef
20.
Li P, Wang X, Li N, et al. Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med. 2006;18:505–10.PubMed
21.
Zhang Y, Wang X, Xiang Z, et al. Promotion of cellular migration and apoptosis resistance by a mouse eye-specific phosphatidylethanolamine-binding protein. Int J Mol Med. 2007;19:55–63.PubMed
22.
Yeung K, Janosch P, McFerran B, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000;20:3079–85.PubMedCrossRef
23.
Li H, Wang X, Li N, et al. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating AKT and deactivating ERK1/2 pathways. J Biol Chem. 2007;282:4943–50.PubMedCrossRef
24.
Winn RA, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005;280:19625–34.PubMedCrossRef
25.
Niquet J, Wasterlain CG. Bim, Bad, and Bax: a deadly combination in epileptic seizures. J Clin Invest. 2004;113:960–2.PubMed
26.
Jeong SJ, Pise-Masison CA, Radonovich MF, et al. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene. 2005;24:6719–28.PubMedCrossRef
27.
Ahmed NN, Grimes HL, Bellacosa A, et al. Transduction of interleukin-2 antiapoptotic and proliferative signals via AKT protein kinase. Proc Natl Acad Sci USA. 1997;94:3627–32.PubMedCrossRef
28.
Lee MY, Ryu JM, Lee SH, et al. Lipid rafts play an important role for maintenance of embryonic stem cell self-renewal. J Lipid Res. 2010;51:2082–9.PubMedCrossRef
29.
Qian Y, Corum L, Meng Q, et al. PI3K induced actin filament remodeling through AKT and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol. 2004;286:C153–63.PubMedCrossRef
30.
Syed DN, Afaq F, Sarfaraz S, et al. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 2008;231:52–60.PubMedCrossRef
31.
Grille SJ, Bellacosa A, Upson J, et al. The protein kinase AKT induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63:2172–8.PubMed
32.
Zuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem. 2011;112:2508–17. doi:10.​1002/​jcb.​23175.PubMedCrossRef
33.
Kim D, Kim S, Koh H, et al. AKT/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001;15:1953–62.PubMedCrossRef
34.
Yu HG, Li JY, Yang YN, et al. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett. 2003;195:43–51.PubMedCrossRef
35.
Maroni P, Matteucci E, Luzzati A, et al. Nuclear co-localization and functional interaction of COX-2 and HIF-1alpha characterize bone metastasis of human breast carcinoma. Breast Cancer Res Treat. 2010;129:433–50. doi:10.​1007/​s10549-010-1240-1.PubMedCrossRef
36.
Tahanian E, Sanchez LA, Shiao TC, et al. Flavonoids targeting of IkappaB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells. Drug Des Devel Ther. 2011;5:299–309.PubMed
37.
Tammali R, Saxena A, Srivastava SK, et al. Aldose reductase inhibition prevents hypoxia-induced increase in HIF-1{alpha} and VEGF by regulating the 26S proteasome mediated protein degradation in human colon cancer cells. J Biol Chem. 2011;286:24089–100.PubMedCrossRef
38.
Shash E, Peccatori FA, Azim Jr HA. Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis. 2011;3:57–64.
39.
Xiao DK, He JX. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2:154–9.
40.
Yang HH, Zhang Q, He JX, Lu WJ. Regulation of calcium signaling in lung cancer. J Thorac Dis. 2010;2:52–6.
Metadata
Title
The expression of PEBP4 protein in lung squamous cell carcinoma
Authors
Gui-Ping Yu
Guo-Qiang Chen
Song Wu
Kai Shen
Yong Ji
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0230-1

Other articles of this Issue 6/2011

Tumor Biology 6/2011 Go to the issue

Research Article

Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma

Research Article

Increased N-myc downstream-regulated gene 1 expression is associated with breast atypia-to-carcinoma progression

Research Article

The expression of p33ING1, p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer

Research Article

Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients

Review

PDGF: the nuts and bolts of signalling toolbox

Research Article

Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits